vs
Apellis Pharmaceuticals, Inc.（APLS）与Live Oak Bancshares, Inc.（LOB）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Live Oak Bancshares, Inc.的1.4倍（$199.9M vs $145.5M），Live Oak Bancshares, Inc.净利率更高（19.2% vs -29.5%，领先48.7%），Live Oak Bancshares, Inc.同比增速更快（18.4% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Live Oak Bancshares, Inc.是一家美国金融控股公司，旗下子公司Live Oak Bank总部位于北卡罗来纳州威尔明顿，业务覆盖美国全部50个州，专注为小企业主提供金融服务，2022年按放贷金额计是美国SBA 7(a)贷款项目的头部放贷机构。
APLS vs LOB — 直观对比
营收规模更大
APLS
是对方的1.4倍
$145.5M
营收增速更快
LOB
高出24.3%
-5.9%
净利率更高
LOB
高出48.7%
-29.5%
两年增速更快
APLS
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $145.5M |
| 净利润 | $-59.0M | $27.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 19.2% |
| 营收同比 | -5.9% | 18.4% |
| 净利润同比 | -62.2% | 187.6% |
| 每股收益（稀释后） | $-0.40 | $0.60 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSLOB
| Q1 26 | — | $145.5M | ||
| Q4 25 | $199.9M | $161.9M | ||
| Q3 25 | $458.6M | $146.1M | ||
| Q2 25 | $178.5M | $143.7M | ||
| Q1 25 | $166.8M | $126.1M | ||
| Q4 24 | $212.5M | $116.9M | ||
| Q3 24 | $196.8M | $129.9M | ||
| Q2 24 | $199.7M | $125.5M |
净利润APLSLOB
| Q1 26 | — | $27.9M | ||
| Q4 25 | $-59.0M | $46.2M | ||
| Q3 25 | $215.7M | $26.5M | ||
| Q2 25 | $-42.2M | $23.4M | ||
| Q1 25 | $-92.2M | $9.7M | ||
| Q4 24 | $-36.4M | $9.9M | ||
| Q3 24 | $-57.4M | $13.0M | ||
| Q2 24 | $-37.7M | $27.0M |
营业利润率APLSLOB
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 38.2% | ||
| Q3 25 | 48.7% | 25.0% | ||
| Q2 25 | -18.6% | 21.7% | ||
| Q1 25 | -50.0% | 10.4% | ||
| Q4 24 | -12.3% | 11.3% | ||
| Q3 24 | -24.0% | 13.7% | ||
| Q2 24 | -14.7% | 28.7% |
净利率APLSLOB
| Q1 26 | — | 19.2% | ||
| Q4 25 | -29.5% | 28.5% | ||
| Q3 25 | 47.0% | 18.1% | ||
| Q2 25 | -23.6% | 16.3% | ||
| Q1 25 | -55.3% | 7.7% | ||
| Q4 24 | -17.1% | 8.5% | ||
| Q3 24 | -29.2% | 10.0% | ||
| Q2 24 | -18.9% | 21.5% |
每股收益（稀释后）APLSLOB
| Q1 26 | — | $0.60 | ||
| Q4 25 | $-0.40 | $0.96 | ||
| Q3 25 | $1.67 | $0.55 | ||
| Q2 25 | $-0.33 | $0.51 | ||
| Q1 25 | $-0.74 | $0.21 | ||
| Q4 24 | $-0.30 | $0.22 | ||
| Q3 24 | $-0.46 | $0.28 | ||
| Q2 24 | $-0.30 | $0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.3B |
| 总资产 | $1.1B | $15.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSLOB
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
股东权益APLSLOB
| Q1 26 | — | $1.3B | ||
| Q4 25 | $370.1M | $1.2B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $1.0B | ||
| Q4 24 | $228.5M | $999.0M | ||
| Q3 24 | $237.1M | $1.0B | ||
| Q2 24 | $264.3M | $961.0M |
总资产APLSLOB
| Q1 26 | — | $15.3B | ||
| Q4 25 | $1.1B | $15.1B | ||
| Q3 25 | $1.1B | $14.7B | ||
| Q2 25 | $821.4M | $13.8B | ||
| Q1 25 | $807.3M | $13.6B | ||
| Q4 24 | $885.1M | $12.9B | ||
| Q3 24 | $901.9M | $12.6B | ||
| Q2 24 | $904.5M | $11.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSLOB
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $158.2M | ||
| Q3 25 | $108.5M | $62.3M | ||
| Q2 25 | $4.4M | $49.2M | ||
| Q1 25 | $-53.4M | $-33.0M | ||
| Q4 24 | $19.4M | $156.8M | ||
| Q3 24 | $34.1M | $47.4M | ||
| Q2 24 | $-8.3M | $29.5M |
自由现金流APLSLOB
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $143.5M | ||
| Q3 25 | $108.3M | $60.6M | ||
| Q2 25 | $4.4M | $47.8M | ||
| Q1 25 | $-53.4M | $-35.3M | ||
| Q4 24 | $19.3M | $107.5M | ||
| Q3 24 | — | $41.0M | ||
| Q2 24 | $-8.4M | $12.3M |
自由现金流率APLSLOB
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 88.6% | ||
| Q3 25 | 23.6% | 41.4% | ||
| Q2 25 | 2.5% | 33.3% | ||
| Q1 25 | -32.0% | -28.0% | ||
| Q4 24 | 9.1% | 91.9% | ||
| Q3 24 | — | 31.6% | ||
| Q2 24 | -4.2% | 9.8% |
资本支出强度APLSLOB
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 9.1% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 1.8% | ||
| Q4 24 | 0.0% | 42.2% | ||
| Q3 24 | 0.0% | 4.9% | ||
| Q2 24 | 0.0% | 13.7% |
现金转化率APLSLOB
| Q1 26 | — | — | ||
| Q4 25 | — | 3.42× | ||
| Q3 25 | 0.50× | 2.35× | ||
| Q2 25 | — | 2.10× | ||
| Q1 25 | — | -3.39× | ||
| Q4 24 | — | 15.84× | ||
| Q3 24 | — | 3.64× | ||
| Q2 24 | — | 1.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
LOB
暂无分部数据
